9.51
price up icon2.04%   0.18
 
loading
Schlusskurs vom Vortag:
$9.33
Offen:
$9.43
24-Stunden-Volumen:
52,048
Relative Volume:
0.08
Marktkapitalisierung:
$561.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-4.3227
EPS:
-2.2
Netto-Cashflow:
$-8.40M
1W Leistung:
-14.54%
1M Leistung:
-20.07%
6M Leistung:
-30.26%
1J Leistung:
+19.75%
1-Tages-Spanne:
Value
$9.25
$9.7123
1-Wochen-Bereich:
Value
$8.97
$11.19
52-Wochen-Spanne:
Value
$6.93
$30.96

Immunome Inc Stock (IMNM) Company Profile

Name
Firmenname
Immunome Inc
Name
Telefon
610-321-3700
Name
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Name
Mitarbeiter
105
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IMNM's Discussions on Twitter

Vergleichen Sie IMNM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
IMNM 9.47 561.50M 0 -106.81M -8.40M -2.20
VRTX 447.51 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.90 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.12 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.20 24.49B 3.30B -501.07M 1.03B 11.54

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-05-31 Eingeleitet Piper Sandler Overweight
2024-04-30 Eingeleitet JP Morgan Overweight
2024-04-15 Eingeleitet Guggenheim Buy
2024-01-29 Eingeleitet Leerink Partners Outperform
2023-12-19 Eingeleitet Wedbush Outperform
2021-10-29 Eingeleitet Cantor Fitzgerald Overweight
Alle ansehen

Immunome Inc Aktie (IMNM) Neueste Nachrichten

pulisher
03:55 AM

Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World

03:55 AM
pulisher
Nov 18, 2024

Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace

Nov 14, 2024
pulisher
Nov 14, 2024

Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Immunome, Inc. Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome Inc (IMNM) Q3 2024 Earnings: Revenue Surpasses Estimates at $2.91M, GAAP EPS Misses at -$0.78 - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome Reports $47.1M Q3 Loss, Advances Cancer Pipeline with Strong Cash Position | IMNM Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

(IMNM) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome earnings missed by $0.24, revenue topped estimates - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 10, 2024

Immunome (NASDAQ:IMNM) Shares Gap Up – Still a Buy? - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN

Nov 09, 2024
pulisher
Nov 08, 2024

Analyst Expectations For Immunome's Future - Benzinga

Nov 08, 2024
pulisher
Nov 08, 2024

Immunome (NASDAQ:IMNM) Shares Gap UpTime to Buy? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Immunome (NASDAQ:IMNM) Now Covered by Stephens - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Immunome, Inc. (NASDAQ:IMNM) Stake Reduced by Wealth Enhancement Advisory Services LLC - Defense World

Nov 08, 2024
pulisher
Nov 05, 2024

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - The Bakersfield Californian

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Immunome (NASDAQ:IMNM) Trading Up 8.7%Time to Buy? - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Learn to Evaluate (IMNM) using the Charts - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 01, 2024

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World

Nov 01, 2024
pulisher
Oct 31, 2024

Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire

Oct 29, 2024
pulisher
Oct 29, 2024

Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 15.2% in October - MarketBeat

Oct 29, 2024
pulisher
Oct 25, 2024

Immunome's (IMNM) Outperform Rating Reiterated at Wedbush - MarketBeat

Oct 25, 2024
pulisher
Oct 18, 2024

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - The Bakersfield Californian

Oct 18, 2024
pulisher
Oct 18, 2024

IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan

Oct 18, 2024
pulisher
Oct 15, 2024

Immunome (IMNM) Price Target Increased by 179.17% to 34.17 - MSN

Oct 15, 2024
pulisher
Oct 15, 2024

Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Cubist Systematic Strategies LLC Decreases Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Metrics Exploration: Understanding Immunome Inc (IMNM) Through Ratios - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Sei Investments Co. Cuts Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

(IMNM) Investment Analysis and Advice - Stock Traders Daily

Oct 11, 2024
pulisher
Oct 10, 2024

Insider Selling: Rosett Max, Immunome Inc [IMNM] Chief Financial Officer divested 14,380 shares - Knox Daily

Oct 10, 2024

Finanzdaten der Immunome Inc-Aktie (IMNM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Immunome Inc-Aktie (IMNM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Rosett Max
Chief Financial Officer
Sep 19 '24
Sale
16.01
14,380
230,224
47,476
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):